ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AUTL vs ALLO // PIOTROSKI F-SCORE QUALITY

Autolus Therapeutics plc (NASDAQ) VS. Allogene Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AUTL 1 — ALLO 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUTL VS. ALLO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AUTL ALLO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin -27.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.6 29.3 +7.29 AUTL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $420.5M $431.9M -$11.3M ALLO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AUTL REV ALLO REV AUTL GROSS % ALLO GROSS % AUTL FCF ALLO FCF
FY 2025 $75.4M $0 -27.8% — -$302.6M -$149.6M
FY 2024 $10.1M $22.0K -12.5% — -$228.3M -$201.0M
FY 2023 $1.7M $95.0K — — -$145.6M -$237.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUTL // BETA —
ALLO // BETA —